Zydus Lifesciences on Saturday said it has received approval from the U.S. health regulator to market a generic anti-epileptic medication.
The company has received approval from the U.S. Food and Drug Administration to manufacture and market Lacosamide Tablets in multiple strengths, the drug firm said in a statement.
Lacosamide is indicated to treat partial-onset seizures. It is also used with other medicines to treat primary generalized tonic-clonic seizures.
The company said it will manufacture the product at the group's formulation manufacturing facility in Moraiya, Ahmedabad.
ADVERTISEMENT
As per IQVIA data, Lacosamide Tablets had annual sales of $249 million in the US.
Add us to your Preferences
Set as your preferred source on Google
ADVERTISEMENT
RECOMMENDED FOR YOU
Upcoming IPO: Aeroplane Basmati Maker Gets SEBI Nod For Rs 550 Crore Issue
Biocon Unit Gets USFDA Nod For Generic Rifaximin Tablets Used To Treat IBS-D
Metro Brands Gets 'Sell' From HDFC Securities On Stretched Valuations — Check Target Price
Buy Birla Corp, Add ACC Shares Lists Yes Securities Among Others In Cement Space; Q2 Results Preview
POPULAR
1
Pakistan, Afghanistan Agree On Ceasefire Amid Deadly Clashes
2
US Ready To Hit China With Tariffs Over Russian Oil, But Wants Europe To Join
3
Apple Unveils iPad Pro With M5 Chip In India, Pre-Orders Open Now — Check Price, Features
4
China Moves WTO With Complaint Against India's EV Subsidies
5